The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: A Double-Blind, Placebo-Controlled Laboratory Study

Neuropsychopharmacology

Volumn 40, Issue 10, 2015, Pages 2347-2356

  Ray, Lara A ^a   Bujarski, Spencer ^a   Courtney, Kelly E ^a   Moallem, Nathasha R ^a   Lunny, Katy ^a   Roche, Daniel ^a   Leventhal, Adam M ^b   Shoptaw, Steve ^a   Heinzerling, Keith ^a   London, Edythe D ^a,c   Miotto, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE; NALTREXONE; PLACEBO; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; ASSOCIATION; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DSM-IV; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; METHAMPHETAMINE DEPENDENCE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; WITHDRAWAL SYNDROME; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CROSSOVER PROCEDURE; DRUG EFFECTS; HEART RATE; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; SEXUAL DEVELOPMENT; TIME FACTOR; YOUNG ADULT;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CROSS-OVER STUDIES; CUES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SEX CHARACTERISTICS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 84939251368     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.83     Document Type: Article

References (56)

1. Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T (2004). Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 1021: 272-276.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003-2017.
3. Bohn MJ, Krahn DD, Staehler BA (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19: 600-606.
4. Brensilver M, Heinzerling KG, Shoptaw S (2013). Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev 32: 449-460.
5. Chiu CT, Ma T, Ho IK (2005). Attenuation of methamphetamineinduced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull 67: 100-109.
6. Chiu CT, Ma T, Ho IK (2006). Methamphetamine-induced behavioral sensitization in mice: alterations in mu-opioid receptor. J Biomed Sci 13: 797-811.
7. Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D et al (2012). Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry 72: 371-377.
8. Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA et al (2013). Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology 38: 2427-2438.
9. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM et al (1993). Pharmacokinetics of methamphetamine selfadministered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21: 717-723.
10. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B et al (1997). Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14: 529-534.
11. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). Pharmacotherapy of methamphetamine addiction: an update. Subst Abus 29: 31-49.
12. Fatseas M, Denis C, Massida Z, Verger M, Franques-Reneric P, Auriacombe M (2011). Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals. Biol Psychiatry 70: 720-727.
13. First MB (2005). Structured Clinical Interview for DSM-IV-TR Axis I Disorders: Patient Edition. USA: Biometrics Research Department, Columbia University: New York, NY, USA.
14. Fisher RA (1922). On the interpretation of x(2) from contingency tables, and the calculation of P. J R Stat Soc 85: 87-94.
15. Ford CP, Mark GP, Williams JT (2006). Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26: 2788-2797.
16. Ghitza UE, Preston KL, Epstein DH, Kuwabara H, Endres CJ, Bencherif B et al (2010). Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry 68: 697-703.
17. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M et al (2005). Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57: 1573-1582.
18. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino ML et al (2008). Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) 200: 475-486.
19. Grant JE, Odlaug BL, Kim SW (2010). A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 20: 823-828.
20. Haggkvist J, Lindholm S, Franck J (2008). The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. Behav Brain Res 197: 219-224.
21. Haggkvist J, Lindholm S, Franck J (2009). The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. Behav Brain Res 197: 219-224.
22. Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Thurmond A, Comer SD et al (2008). Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 33: 1847-1855.
23. Herz A (1997). Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 129: 99-111.
24. Itzhak Y, Ali SF (2002). Behavioral consequences of methamphetamine- induced neurotoxicity in mice: Relevance to the psychopathology of methamphetamine addiction. Ann N Y Acad Sci 965: 127-135.
25. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J (2008a). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165: 1442-1448.
26. Jayaram-Lindstrom N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J (2008b). Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 33: 1856-1863.
27. Jayaram-Lindstrom N, Wennberg P, Hurd YL, Franck J (2004). Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 24: 665-669.
28. Jimenez-Gomez C, Winger G, Dean RL, Deaver DR, Woods JH (2011). Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys. Behav Pharmacol 22: 87-90.
29. Johnson BA (2008). Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol 75: 34-56.
30. Kreek MJ (1996). Opiates, opioids and addiction. Mol Psychiatry 1: 232-254.
31. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF (1988). Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29: 1207-1211.
32. Levine J, Schooler NR (1986). SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343-381.
33. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML et al (2012). Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17: 513-527.
34. MacKillop J (2006). Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res 30: 1315-1321.
35. Mason BJ, Higley AE (2013). A translational approach to novel medication development for protracted abstinence. Curr Top Behav Neurosci 13: 647-670.
36. Mick I, Myers J, Stokes PR, Erritzoe D, Colasanti A, Bowden-Jones H et al (2014). Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. Int J Neuropsychopharmacol 17: 2069-2074.
37. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR (1987). Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol 96: 122-126.
38. Morean ME, deWit H, King AC, SofuogluM, Rueger SY, O'Malley SS (2013). The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) 227: 177-192.
39. Newton TF, Reid MS, De La Garza R, Mahoney JJ, Abad A, Condos R et al (2008). Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetaminedependent volunteers. Int J Neuropsychopharmacol 11: 1037-1045.
40. Newton TF, Roache JD, De La Garza R 2nd, Fong T, Wallace CL, Li SH et al (2006). Bupropion reduces methamphetamineinduced subjective effects and cue-induced craving. Neuropsychopharmacology 31: 1537-1544.
41. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
42. O'Malley SS, Krishnan-Sarin S, Farren C, O'Connor PG (2000). Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioidmediated effects. J Clin Psychopharmacol 20: 69-76.
43. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED (2014a). Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology (Berl) 231: 3843-3853.
44. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED (2014b). Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse 41: 35-44.
45. Ray LA, Hutchison KE, Tartter M (2010). Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharm Des 16: 2149-2158.
46. Schad CA, Justice JB Jr., Holtzman SG (1996). Differential effects of delta- and mu-opioid receptor antagonists on the amphetamineinduced increase in extracellular dopamine in striatum and nucleus accumbens. J Neurochem 67: 2292-2299.
47. Seo D, Lacadie CM, Tuit K, Hong KI, Constable RT, Sinha R (2013). Disrupted ventromedial prefrontal function, alcohol craving, and subsequent relapse risk. JAMA Psychiatry 70: 727-739.
48. Sobell LC, Sobell MB, Leo GI, Cancilla A (1988). Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83: 393-402.
49. Substance Abuse and Mental Health Services Administration (SAMHSA) (2013). Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration: Rockville, MD, USA.
50. Suzuki T, Mori T, Tsuji M, Misawa M, Nagase H (1997). The role of delta-opioid receptors in the discriminative stimulus properties of a low dose of methamphetamine. Eur J Pharmacol 331: 1-8.
51. Swift R, Oslin DW, Alexander M, Forman R (2011). Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 72: 1012-1018.
52. Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Fohr J et al (2012). Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 169: 531-536.
53. Tolliver BK, McRae-Clark AL, Saladin M, Price KL, Simpson AN, DeSantis SM et al (2010). Determinants of cue-elicited craving and physiologic reactivity in methamphetaminedependent subjects in the laboratory. Am J Drug Alcohol Abuse 36: 106-113.
54. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
55. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ et al (2008). Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology 33: 653-665.
56. Zalewska-Kaszubska J, Gorska D, Dyr W, Czarnecka E (2006). Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacol Biochem Behav 85: 155-159.